GW&K Investment Management’s Emergent Biosolutions EBS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | – | Sell |
-45
| Closed | -$2K | – | 819 |
|
|
2021
Q4 | $2K | Sell |
45
-499,773
| -100% | -$22.6M | ﹤0.01% | 384 |
|
|
2021
Q3 | $25M | Sell |
499,818
-4,819
| -1% | -$292K | 0.22% | 177 |
|
|
2021
Q2 | $31.8M | Buy |
504,637
+4,194
| +0.8% | +$269K | 0.28% | 159 |
|
|
2021
Q1 | $46.5M | Sell |
500,443
-128,738
| -20% | -$13.2M | 0.43% | 84 |
|
|
2020
Q4 | $56.4M | Buy |
629,181
+166,325
| +36% | +$15.3M | 0.59% | 39 |
|
|
2020
Q3 | $47.8M | Buy |
462,856
+101,583
| +28% | +$11M | 0.63% | 37 |
|
|
2020
Q2 | $28.6M | Buy |
361,273
+357,519
| +9,524% | +$26.6M | 0.4% | 102 |
|
|
2020
Q1 | $217K | Sell |
3,754
-2,570
| -41% | -$148K | ﹤0.01% | 298 |
|
|
2019
Q4 | $341K | Sell |
6,324
-380
| -6% | -$20.6K | ﹤0.01% | 311 |
|
|
2019
Q3 | $350K | Buy |
6,704
+10
| +0.1% | +$466 | ﹤0.01% | 303 |
|
|
2019
Q2 | $323K | Sell |
6,694
-15
| -0.2% | -$719 | ﹤0.01% | 315 |
|
|
2019
Q1 | $339K | Buy |
6,709
+9
| +0.1% | +$531 | 0.01% | 281 |
|
|
2018
Q4 | $397K | Buy |
6,700
+48
| +0.7% | +$3.09K | 0.01% | 246 |
|
|
2018
Q3 | $438K | Buy |
6,652
+132
| +2% | +$7.7K | 0.01% | 248 |
|
|
2018
Q2 | $329K | Buy |
6,520
+455
| +8% | +$23.7K | 0.01% | 271 |
|
|
2018
Q1 | $319K | Buy |
6,065
+1,755
| +41% | +$87.5K | 0.01% | 259 |
|
|
2017
Q4 | $200K | Buy |
+4,310
| New | +$181K | ﹤0.01% | 262 |
|
|
2016
Q3 | – | Sell |
-112,307
| Closed | -$3.16M | – | 222 |
|
|
2016
Q2 | $3.16M | Buy |
112,307
+12,274
| +12% | +$481K | 0.07% | 193 |
|
|
2016
Q1 | $3.64M | Buy |
100,033
+46,108
| +86% | +$1.63M | 0.08% | 184 |
|
|
2015
Q4 | $2.16M | Sell |
53,925
-420
| -0.8% | -$14.6K | 0.05% | 186 |
|
|
2015
Q3 | $1.55M | Buy |
54,345
+885
| +2% | +$29.2K | 0.04% | 189 |
|
|
2015
Q2 | $1.76M | Sell |
53,460
-1,665
| -3% | -$51.6K | 0.04% | 194 |
|
|
2015
Q1 | $1.58M | Buy |
55,125
+14,430
| +35% | +$414K | 0.04% | 198 |
|
|
2014
Q4 | $1.11M | Buy |
40,695
+5,590
| +16% | +$133K | 0.03% | 202 |
|
|
2014
Q3 | $748K | Buy |
35,105
+7,980
| +29% | +$183K | 0.02% | 210 |
|
|
2014
Q2 | $609K | Buy |
27,125
+10,770
| +66% | +$251K | 0.02% | 212 |
|
|
2014
Q1 | $413K | Buy |
16,355
+2,005
| +14% | +$50.6K | 0.01% | 207 |
|
|
2013
Q4 | $330K | Buy |
14,350
+2,275
| +19% | +$47.4K | 0.01% | 211 |
|
|
2013
Q3 | $230K | Buy |
12,075
+1,315
| +12% | +$23.5K | 0.01% | 214 |
|
|
2013
Q2 | $155K | Buy |
+10,760
| New | +$156K | 0.01% | 216 |
|
Other funds holding EBS
GW&K Investment Management's EBS Position: Q1 2022 in Review
GW&K Investment Management sold out of Emergent Biosolutions (EBS) in Q1 2022, closing a stake of 45 shares — an estimated $2K sold.
GW&K Investment Management first reported a position in EBS in Q2 2013 and held it in 30 quarters. The position peaked at $56.4M in Q4 2020. 255 funds tracked by Wall St. Rank hold EBS as of Q1 2022.
- GW&K Investment Management reported no remaining Emergent Biosolutions position as of Q1 2022 after selling out during the quarter.
- GW&K Investment Management sold 45 Emergent Biosolutions shares in Q1 2022, an estimated $2K.
- GW&K Investment Management first reported a position in Emergent Biosolutions in Q2 2013 and held it in 30 quarters.
- GW&K Investment Management's Emergent Biosolutions position peaked at $56.4M in Q4 2020.
- 255 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2022.
Based on GW&K Investment Management's 13F filing for Q1 2022, filed 9 May 2022.